Key result
The provided text contains only the journal's editorial board information and lacks any clinical study data or findings.
Why the study?
Does weight-based dosing of tinzaparin yield predictable pharmacodynamic responses in healthy heavy-weight/obese subjects compared to normal-weight subjects?
Population
37 healthy heavy-weight subjects (weight 101-165 kg; BMI 26-61 kg/m2)
Comparison
Tinzaparin single doses administered… vs Historical control normal-weight subjects
Design
Cohort
Authors
Loading...
May support weight-based tinzaparin dosing without BMI adjustment in obesity; hypothesis-generating pending clinical outcome trials.
Does weight-based dosing of tinzaparin yield predictable pharmacodynamic responses in healthy heavy-weight/obese subjects compared to normal-weight subjects?
Weight-adjusted subcutaneous tinzaparin dosing yields a predictable pharmacodynamic response in heavy-weight/obese patients without the need for a maximal absolute dose cap.
Barrett et al. (2002) studied Obesity. Tinzaparin was evaluated. The provided text contains only the journal's editorial board information and lacks any clinical study data or findings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: